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Betaine±homocysteine S-methyltransferase is one of the three
enzymes involved in homocysteine catabolism. It uses betaine as
the methyl donor to convert homocysteine into methionine, also
producing dimethylglycine. Recombinant BHMT from rat liver was
crystallized by the vapour-diffusion method in both native and
seleniomethionyl-labelled forms. Crystals belong to space group P21,
with unit-cell parameters a = 57.8, b = 149.3, c = 96.2 AÊ ,  = 92.9.
Data from native, seleniomethionine-labelled and two heavy-atom
derivatives were collected using synchrotron sources. Self-rotation
function and sedimentation-velocity experiments suggest that the
enzyme is tetrameric with 222 symmetry.
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1. Introduction
Betaine homocysteine methyltransferase
(BHMT; EC 2.1.1.5) is one of the three
enzymes involved in homocysteine catabolism
(Mato et al., 1997). The catalyzed reaction
serves to recover one of the three methylation
equivalents used to synthesize phosphatidyl-
choline through choline oxidation to betaine.
This last compound is the methyl donor that
BHMT uses to convert homocysteine in
methionine, leading also to the production of
dimethylglycine (Barak & Tuma, 1979). In
vitro experiments have shown that both
homocysteine and dimethylglycine are neces-
sary to stabilize BHMT and that dimethyl-
glycine, isovalerate and 3,3-dimethylbutirate
act as inhibitors (Garrow, 1996). This reaction
has been detected to occur almost exclusively
in liver and kidney (Delgado-Reyes et al.,
2001). Decreases in betaine levels have been
observed in choline de®ciencies, along with
decreases in BHMT activity (Finkelstein &
Martin, 1986). In methionine de®ciencies, the
enzyme acquires a key role in the maintenance
of the levels of this essential amino acid for
mammalian growth and development (Finkel-
stein et al., 1982). As for the kidney, betaine has
been proposed to have a role in the protection
of proteins against denaturation arising from
the high level of urea accumulated in the cells
(Coelho-Sampaio et al., 1994). A similar role
has been ascribed to BHMT in Rhesus monkey
lens (Rao et al., 1998). Using vitamin B12-
de®cient diets. a decrease in enzyme activity
has been observed (Williams et al., 1953), while
increases have been detected in low-protein
diets combined with alcohol, alcohol liquid
diets, high-protein diets and diets supple-
mented with methionine (Finkelstein et al.,
1974). Studies in developing rats have shown
that foetal liver activity is lower than in the
adult and that a peak is observed in the ®rst
10 d of the neonate (Klee et al., 1961). More-
over, hydrocortisone and tyroxine treatments
also affect BHMT activity (Klee et al., 1961).
Recently, it has been shown that BHMT
regulates the expression of apolipoprotein B
and hence an increase in related lipoproteins is
observed (Sowden et al., 1999); it has been
located bound to tubulin in liver extracts
(Sandu et al., 2000).
BHMT from rat liver is an oligomer of
identical subunits, each subunit being
composed of 406 amino acids (Forestier et al.,
1996; Garrow, 1996). The protein has been
shown to contain Zn2+ (Millian & Garrow,
1998) linked to three cysteine residues (217,
299 and 300 according to the human sequence;
Breksa & Garrow, 1999). One of the mutations
detected so far in patients with moderate
hyperhomocysteinaemia (G199S) has been
suggested to have an important role in the
secondary structure of the enzyme (Heil et al.,
2000). Gly214 has also been shown to be
essential for activity by random mutagenesis
(Breksa & Garrow, 2002). Recently, crystal-
lization of recombinant human BHMT has
been reported (Bose & Momamy, 2001), but
the three-dimensional structure of this enzyme
remains unknown. Structural studies on
BHMT will help to elucidate the catalytic
mechanism and the function of this enzyme at
the atomic level. This will provide new insights
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into the methionine metabolism and, there-
fore, in the search for drugs to control the
diseases in which the enzyme is involved.
2. Materials and methods
2.1. Expression and purification
Rat-liver RNA was isolated using the
procedure described by Too & Maggio
(1995) and used to obtain the BHMT cDNA
by PCR. For this purpose, oligonucleotides
including the NdeI (50-AGTAGTCAGCA-
TATGGCACCGATTGCC-30) and BamHI
(50-AGTCAGGGATCCCTACTGTGCGG-
ATTTGAATTTTT-30) restriction sites were
designed. The ampli®ed sequence was
treated with the above-mentioned restric-
tion enzymes and cloned in the pET11a
plasmid (Stratagene, Santa Clara, CA,
USA). This plasmid was used to transform
competent Escherichia coli BL21(DE3)
cells. Overnight cultures prepared from a
single colony were used to inoculate 3 l of
LB medium plus ampicillin (100 mg mlÿ1).
The cells were grown until absorbance
( = 600 nm) reached 0.6; a 3 h induction
was then started with 0.5 mM IPTG
(Ambion, Austin, TX, USA). The bacteria
overexpressing BHMT were harvested by
centrifugation and kept frozen at 203 K until
use.
Cell pellets were dissolved in 30 mM
potassium phosphate pH 7.6, 5 mM
2-mercaptoethanol, 2 mM EDTA, 2 mg mlÿ1
aprotinin, 1 mg mlÿ1 pepstatin A,
0.5 mg mlÿ1 leupeptin, 2.5 mg mlÿ1 antipain,
0.5 mM benzamidine, 0.1 mM PMSF (Sigma
Chemical Co., St Louis, MO, USA).
Disruption of the cells was carried out by
sonication at 277 K (15  30 s pulses at 30 s
intervals, output power level 20 in a Branson
250 soni®er). The soluble fraction was
obtained by centrifugation at 100 000g for
1 h and used for further chromatographic
steps. Puri®cation was obtained by using
DEAE-Sephacel (Pharmacia, Uppsala,
Sweden) and Biogel HTP (Bio-Rad,
Hercules, CA, USA) columns as described
by Millian & Garrow (1998) with minor
modi®cations. The puri®ed protein was
stored in 50% glycerol at 203 K until use.
2.2. Determination of the oligomeric state
Samples of puri®ed BHMT in the
concentration range 0.2±0.6 mg mlÿ1 were
used for sedimentation-velocity experi-
ments, which were performed at
50 000 rev minÿ1 and 283 K in a Beckman
Optima XL-A analytical ultracentrifuge
(Beckman Instruments, Inc.) equipped with
absorbance optics, using an An50Ti rotor.
Absorbance scans (0.005 cm step size) were
taken at 280 nm. The sedimentation-velocity
data were analysed with the program
SVEDBERG (Philo, 1997). Sedimentation-
velocity coef®cients were corrected for
solvent composition and temperature to
obtain s20,w (van Holde, 1986).
2.3. Crystallization
The puri®ed protein was initially concen-
trated to 6 mg mlÿ1 by ultra®ltration using
YM-30 membranes (Amicon, Millipore
Corporation, Bedford, MA, USA) in a
solution containing 10 mM Tris±HCl pH 8.2,
0.5 mM EDTA and 1 mM 2-mercapto-
ethanol. All crystallization experiments
were carried out at 291 K on Linbro tissue-
culture plates using the hanging-drop
vapour-diffusion technique. Hanging drops
consisted of 1 ml of protein solution and 1 ml
of reservoir solution. Initial crystallization
conditions were identi®ed using the
commercially available Hampton Research
Crystal Screens I and II (Jancarik & Kim,
1991). Plate-like crystals were observed in
two test solutions: 30% PEG 1500 and 20%
PEG 2000 monomethylether pH 8.5, 0.01 M
NiCl2. These conditions were later re®ned to
the ®nal values indicated in Table 1. For
heavy-atom derivatization, native crystals
were soaked with saturated phenylmercury
acetate (PMA) for 24 h or with 10 mM
AuK(CN)2 for 12 h.
2.4. Preparation and analysis of
SeMetBHMT crystals
To solve the structure by the MAD
method, selenomethionyl BHMT was
produced using the same vector and host
strain under modi®ed conditions. As E. coli
BL21(DE3) is not a methionine auxotroph,
the conditions were chosen to exclude
methionine from the medium and to provide
ample amounts of other amino acids known
to inhibit methionine biosynthesis (van
Duyne et al., 1993). The puri®cation of the
protein was performed following the same
protocol as that described for the native
enzyme. The incorporation of selenium into
selenomethionyl-derivatized protein was
assayed by comparison of the mass of this
form with that of the native protein using
ESI spectrometry. The preparation of
BHMT seleno-l-methionine crystals was
similar to that used to grow the native
crystals.
X-ray ¯uorescence spectra were
measured on station ID14-4 at the ESRF
(Grenoble, France) using a single plate-like
crystal of SeMetBHMT. Calculation of
anomalous scattering factors from the raw
¯uorescence spectrum was performed using
the CHOOCH program (Evans & Pettifer
2001).
2.5. Data collection and processing
Native, SeMetBHMT and heavy-atom
derivative crystals were soaked in cryo-
protectant solutions containing the precipi-
tant and 20% glycerol before being cooled
to 100 K. Diffraction data were collected
using synchrotron radiation at the beamlines
given in Table 1. The different data sets were
processed using the program MOSFLM
(Leslie, 1990) and the CCP4 suite (Colla-
Table 1
Data-collection statistics.
The space group is P21 for all crystals. Values in parentheses are for the highest resolution shell.
Native 1 Native 2
SeMeBHMT
(peak) Hg-BHMT Au-BHMT
Crystallization
conditions
6 mg mlÿ1 protein,
16% PEG 1500
pH 8.5
6 mg mlÿ1 protein,
14% PEG 2K
MME pH 8.5
6 mg mlÿ1 protein,
14% PEG 2K
MME pH 7.5
6 mg mlÿ1 protein,
16% PEG 1500
pH 8.5
6 mg mlÿ1 protein,
16% PEG 1500
pH 8.5
Crystal size (mm) 0.10  0.05
 0.01
0.20  0.10
 0.03
0.20  0.10
 0.01
0.20  0.10
 0.02
0.20  0.10
 0.02
Beamline SRS, Daresbury BM14, ESRF ID14-4, ESRF BM14, ESRF BM14, ESRF
Wavelength (AÊ ) 1.244 1.004 0.979 1.004 1.004
Unit-cell parameters
a (AÊ ) 57.95 57.83 58.25 57.98 57.79
b (AÊ ) 149.87 149.27 152.68 143.20 150.20
c (AÊ ) 96.37 96.25 96.32 95.82 96.10
 () 93.45 92.92 93.33 91.25 93.12
Resolution (AÊ ) 3.2 2.7 3.0 2.8 2.8
Measurements 205332 375917 235069 370419 463031
Unique data 25079 48142 32340 36669 39591
I/(I) 4.5 (1.8) 6.0 (1.8) 5.0 (1.7) 4.6 (1.4) 3.5 (1.4)
Completeness (%) 98.3 (97.9) 99.8 (99.1) 97.0 (97.0) 100.0 (100.0) 97.9 (97.4)
Multiplicity 3.7 (3.7) 4.0 (4.0) 3.2 (2.6) 3.7 (3.7) 3.9 (3.9)
Rmerge² (%) 12.4 (42.0) 8.0 (40.0) 11.9 (41.7) 9.7 (33.2) 10.4 (51.3)
² Rmerge =
PI ÿ hIi=PI.
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borative Computational Project, Number 4,
1994).
3. Results and discussion
Preliminary plate-like crystals
were very thin and consequently
the diffraction pattern was of
very poor quality. Crystallization
conditions were re®ned by
varying several parameters, e.g.
buffer content, pH, temperature,
sample size and the type and
concentration of the precipitant
agent. Plates appeared after 5±
15 d; most of them grew as
twinned clusters and only a few
drops yielded crystals appro-
priate for diffraction experi-
ments (Fig. 1). Screening of
many additives (Additive
Screens, Hampton Research)
was also tried but did not
improve the crystal quality.
Addition of several detergents
(CYMAL-5 and nonyl--d-
glucoside) gave very small
needles that did not progress. In
the case of SeMetBHMT, plate-like crystals
were also obtained, but a new habit was also
observed with the same precipitant agents
and similar conditions as those used to grow
the plate-like crystals (Fig. 2a). Addition of
additives was again investigated, leading to
small hexagonal crystals (Fig. 2b) with either
ATP or spermine in the range 10±100 mM.
These hexagonal crystals reach a maximum
size of 0.04 mm and failed to diffract using a
synchrotron X-ray source. MAD diffraction
data were then collected from the plate-like
crystals. A typical diffraction pattern for
crystals of this habit is shown in Fig. 3. Data
were always collected using synchrotron
sources, as they showed very poor diffrac-
tion using rotating-anode-generated X-rays.
Data-collection statistics for native,
SeMetBHMT and two heavy-atom deriva-
tives are summarized in Table 1. The space
group is P21 for all forms. The molecular
weight of the monomer is 45 kDa; therefore,
assuming two, three or four molecules per
asymmetric unit, the Matthews coef®cient
(Matthews, 1968) would be 4.5, 3.0 or
2.2 AÊ 3 Daÿ1. We have investigated the local
symmetry relating the protomers in the
asymmetric unit using POLARRFN
(Kabsch, 1976) from the CCP4 package.
Several self-rotation functions were
computed in the resolution range 15±3 AÊ ,
with Patterson vectors up to a radius of
integration of 20 AÊ . Analysis of self-rotation
peaks revealed the presence of non-crystal-
lographic twofold symmetry almost along
the a and c axes. The stereographic projec-
tion ( = 180 section) of the self-rotation is
shown in Fig. 4. On the other hand, the
sedimentation-velocity experiments give an
estimated molecular weight of 160 kDa,
which indicates a tetrameric aggregation
state for BHMT. Taking into account these
data and the local symmetry, we consider the
possibility of the asymmetric unit containing
a tetramer with point symmetry 222 and a
solvent content of 44% in the cell (VM =
2.2 AÊ 3 Daÿ1). This tetrameric aggregation of
rat-liver BHMT is contradictory to
previously reported data obtained by gel-
®ltration chromatography, where an
apparent molecular weight of 270 kDa was
calculated (Skiba et al., 1982). Those data
were ascribed to the presence of the protein
as an hexamer and differences could arise
Figure 1
Plate-like crystals of recombinant rat-liver BHMT
(habit 1). The maximum dimensions are 0.20  0.10
 0.03 mm.
Figure 2
Effect of the addition of ATP or spermine on
SeMetBHMT crystals: (a) habit 2 with no additive
and (b) habit 3, grown in the same conditions and
50 mM ATP.
Figure 3
X-ray diffraction pattern from a crystal of native BHMT using a
synchrotron source. The outer resolution shell is 2.5 AÊ .
Figure 4
Plot of the self-rotation function of BHMT native
crystals using data in the range 15±3 AÊ and a 20 AÊ
radius of integration in the  = 180 section. The view
is down the b axis. ’ = 0 and 90 correspond to the a
and c* axes, respectively.
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from the use of globular protein standards.
This tetrameric association of recombinant
human BHMT has been described
previously (Bose & Momamy, 2001), but in
that case the crystal was grown from the
protein containing a polyhistidine tag at the
N-terminus of the chain.
The X-ray ¯uorescence spectrum was
measured at the selenium K edge for a
SeMetBHMT crystal and the anomalous
scattering factors were calculated as a func-
tion of X-ray energy. This gives an f 0
(in¯ection point) and an f 00 (peak) of ÿ13.2
and 10.5, respectively. Analysis of MAD
data is under way using direct and Patterson
techniques. The diffraction pattern is very
anisotropic, this effect being particularly
signi®cant in the case of SeMetBHMT
crystals. This leads to poor data in the 3±4 AÊ
resolution shell. As an alternative, data from
the two heavy-atom derivatives are also
under study.
References
Barak, A. J. & Tuma, D. J. (1979). Lipids, 14, 860±
863.
Bose, N. & Momamy, C. (2001). Acta Cryst. D57,
431±433.
Breksa, A. P. III & Garrow, T. A. (1999).
Biochemistry, 38, 13991±13998.
Breksa, A. P. III & Garrow, T. A. (2002). Arch.
Biochem. Biophys. 399, 73±80.
Coelho-Sampaio, T., Ferreira, S. T., Castro, E. J. Jr
& Vieyra, A. (1994). Eur. J. Biochem. 221,
1103±1110.
Collaborative Computational Project, Number 4
(1994). Acta Cryst. D50, 760±763.
Delgado-Reyes, C. V., Wallig, M. A. & Garrow,
T. A. (2001). Arch. Biochem. Biophys. 393, 184±
186.
Duyne, G. D. van, Standaert, R. F., Karplus, P. A.,
Schreiber, S. L. & Clardy, J. (1993). J. Mol. Biol.
276, 523±530.
Evans, G. & Pettifer, R. F. (2001). J. Appl. Cryst.
34, 82±86.
Finkelstein, J. D., Cello, J. P. & Kyle, W. E. (1974).
Biochem. Biophys. Res. Commun. 61, 525±
531.
Finkelstein, J. D., Harris, B. J., Martin, J. J. & Kyle,
W. E. (1982). Biochem. Biophys. Res. Commun.
108, 344±348.
Finkelstein, J. D. & Martin, J. J. (1986). J. Biol.
Chem. 261, 1582±1587.
Forestier, M., Reichen, J. & Solioz, M. (1996).
Biochem. Biophys. Res. Commun. 225, 377±383.
Garrow, T. A. (1996). J. Biol. Chem. 271, 22831±
22838.
Heil, S. G., Lievers, K. J., Boers, G. H., Verhoef, P.,
den Heijer, M., Trijbels, F. J. & Blom, H. J.
(2000). Mol. Genet. Metab. 71, 511±519.
Holde, K. E. van (1986). Physical Biochemistry,
2nd ed., pp. 110±136. New Jersey, USA:
Prentice-Hall.
Jancarik, J. & Kim, S.-H. (1991). J. Appl. Cryst. 24,
409±411.
Kabsch, W. (1976). Acta Cryst. A32, 922±923.
Klee, W. A., Richards, H. H. & Cantoni, G. L.
(1961). Biochim. Biophys. Acta, 54, 157±164.
Leslie, A. G. W. (1990). Crystallographic
Computing. Oxford University Press.
Mato, J. M., Alvarez, L., Ortiz, P. & Pajares, M. A.
(1997). Pharmacol. Ther. 73, 265±280.
Matthews, B. W. (1968). J. Mol. Biol. 33, 491±
497.
Millian, N. S. & Garrow, T. A. (1998). Arch.
Biochem. Biophys. 356, 93±98.
Philo, J. S. (1997). Biophys. J. 72, 435±444.
Rao, P. V., Garrow, T. A., John, F., Garland, D.,
Millian, N. S. & Zigler, J. S. Jr (1998). J. Biol.
Chem. 273, 30669±30674.
Sandu, C., Nick, P., Hess, D., Schiltz, E., Garrow,
T. A. & Brandsch, R. (2000). J. Biol. Chem. 381,
619±622.
Skiba, W. E., Taylor, M. P., Wells, M. S., Mangum,
J. H. & Awad, W. M. Jr (1982). J. Biol. Chem.
257, 14944±14948.
Sowden, M. P., Collins, H. L., Smith, H. C.,
Garrow, T. A., Sparks, J. D. & Sparks, C. E.
(1999). Biochem. J. 341, 639±645.
Too, H. P. & Maggio, J. E. (1995). Peptides, 16, 45±
53.
Williams, J. N. Jr, Monson, W. J., Sreenivasan, A.,
Dietrich, L. S., Harper, A. E. & Elvehjem, C. A.
(1953). J. Biol. Chem. 202, 151±156.
